Anvisa authorizes research with tetravalent vaccine for Influenza
Anvisa authorizes research with a tetravalent influenza vaccine. In the clinical trial, participants between 6 and 35 months will be...
Anvisa authorizes research with a tetravalent influenza vaccine. In the clinical trial, participants between 6 and 35 months will be...